NovoCure Ltd is an oncology company with a proprietary platform technology in the United States... Show more
a commercial-stage oncology company
Industry MedicalNursingServices
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RAVI | 75.22 | 0.01 | +0.01% |
| Northern Trust Ultra-Short Income ETF (RAVI) | |||
| AKAF | 33.33 | N/A | N/A |
| Frontier Economic Fund | |||
| ILS | 20.40 | N/A | -0.02% |
| Brookmont Catastrophic Bond ETF | |||
| AVDS | 79.20 | -0.39 | -0.49% |
| Avantis International Small Cap Equity ETF (AVDS) | |||
| MAGA | 55.02 | -0.31 | -0.57% |
| Truth Social America First ETF (MAGA) | |||
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with BLFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | -0.18% | ||
| BLFS - NVCR | 39% Loosely correlated | -0.43% | ||
| ALGN - NVCR | 38% Loosely correlated | -1.40% | ||
| AZTA - NVCR | 38% Loosely correlated | -1.16% | ||
| TWST - NVCR | 37% Loosely correlated | +7.35% | ||
| A - NVCR | 35% Loosely correlated | +0.08% | ||
More | ||||
| Ticker / NAME | Correlation To NVCR | 1D Price Change % |
|---|---|---|
| NVCR | 100% | -0.18% |
| Medical/Nursing Services industry (141 stocks) | -1% Poorly correlated | +0.03% |
| Health Services industry (242 stocks) | -1% Poorly correlated | -0.13% |
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 312 of 352 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 70 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for NVCR turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
NVCR moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVCR crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 65 cases where NVCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +3.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 209 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 93 of 124 cases where NVCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NVCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.747) is normal, around the industry mean (10.643). NVCR's P/E Ratio (1465.370) is considerably higher than the industry average of (100.549). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.062). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (39.536).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.